D-0123-2021 Class II Terminated

Recalled by Shilpa Medicare Limited — Polepally, Jadcherla, N/A

FDA drug recall D-0123-2021 was initiated by Shilpa Medicare Limited on Dec 8, 2020 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Mar 11, 2022). Affected quantity: 6,560 vials.

Recall Details

Product Type
Drugs
Report Date
Dec 16, 2020
Initiation Date
Dec 8, 2020
Termination Date
Mar 11, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6,560 vials

Product Description

Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Single Dose Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72606-558-01.

Reason for Recall

CGMP Deviations

Distribution Pattern

Nationwide in the U.S.

Code Information

Lot #: 7S10227A, Exp. 10/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0123-2021
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0123-2021. Report a data issue: hello@regdatalab.com.